Introduction: Our interest was provoked by severe isolated thrombocytopenia (48x10 / 9 / L) in a baby born by Caesarean section. It was a newborn - firstborn after two consecutive spontaneous abortions after the third month of pregnancy.
Materials and Methods: As a material, we used capillary blood taken with an EDTA anticoagulant, tested on an automatic hematology counter Mindray-BC-3000Plus and a blood smear stained by Romanowsky-Giemsa. The mother’s Rh group, as determined by the pregnancy record, was positive.
Results and Discussion: Laboratory results showing thrombocytopenia, abortions identified from a past history, and the absence of visible genetic abnormalities in the baby have led to a suspicion of fetal/neonatal alloimmune thrombocytopenia (F/NAIT).
Conclusion: Although many cases are mild, NAIT is one of the most common causes of severe thrombocytopenia and intracranial hemorrhage in the fetus and the newborn. The diagnosis of NAIT should be considered in the differential diagnosis plan whenever the newborn is with severe thrombocytopenia.
Curtis BR. Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia. Br J Haematol. 2015;171(5):671–68
Basire A, Picard C. Platelet allo-antibodies identification strategies for preventing and managing platelet refractoriness. Transfus Clin Biol. 2014;21(4-5):193–206 ).
Peterson JA, Gitter ML, Kanack A, Curtis B, McFarland J, Bougie D, Aster R. New low-frequency platelet glycoprotein polymorphisms associated with neonatal alloimmune thrombocytopenia. Transfusion. 2010;50:324–33
Wang Y, Andrews M, Yang Y, et al. Platelets in thrombosis and hemostasis: old topic with new mechanisms[J] Cardiovasc Hematol Disord Drug Targets. 2012;12:126–132.
Rossi KQ, Lehman KJ, O’Shaughnessy RW. Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. J Matern Fetal Neonatal Med. 2016;29:1783–1788.
Bussel JB, Primiani A. Fetal and neonatal alloimmune thrombocytopenia: progress and ongoing debates. Blood Rev. 2008;22:33–52
Rossi KQ, Lehman KJ, O’Shaughnessy RW. Effects of antepartum therapy for fetal alloimmune thrombocytopenia on maternal lifestyle. J Matern Fetal Neonatal Med. 2016;29:1783–1788. ).
Delbos F, Bertrand G, Croisille L, Ansart-Pirenne H, Bierling P, Kaplan C. Fetal and neonatal alloimmune thrombocytopenia: predictive factors of intracranial hemorrhage. Transfusion. 2016;56(1):59–66
Ohto H, Miura S, Ariga H, Ishii T, Fujimori K, Morita S, Collaborative Study G. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med. 2004;14(6):399–408
Kamphuis MM, Tiller H, van den Akker ES, Westgren M, Tiblad E, Oepkes D. Fetal and Neonatal Alloimmune Thrombocytopenia: Management and Outcome of a Large International Retrospective Cohort. Fetal Diagn Ther. 2017;41(4):251–7
Ohto H, Yamaguchi T, Takeuchi C, Tohyama Y, Sato A, Morita S. Anti-HPA-5b-induced neonatal alloimmune thrombocytopenia: antibody titre as a predictor. Collaborative study group. Br J Haematol. 2000;110(1):223–227
Bertrand G, Martageix C, Jallu V, Vitry F, Kaplan C. Predictive value of sequential maternal anti-HPA-1a antibody concentrations for the severity of fetal alloimmune thrombocytopenia. Journal of thrombosis and haemostasis: JTH. 2006;4(3):628–637
Hayashi T, Hirayama F. Advances in alloimmune thrombocytopenia: perspectives on current concepts of human platelet antigens, antibody detection strategies, and genotyping. Blood transfusion = Trasfusione del sangue. 2015;13(3):380–390
Kamphuis M, Paridaans N, Winkelhorst D, et al. Lower-dose intravenous immunoglobulins for the treatment of fetal and neonatal alloimmune thrombocytopenia: a cohort study. Transfusion. 2016;56:2308–2313
Sonneveld ME, Natunen S, Sainio S, et al. Glycosylation pattern of anti-platelet IgG is stable during pregnancy and predicts clinical outcome in alloimmune thrombocytopenia. Br J Haematol. 2016;174:310–320
Kapur R, Heitink-Polle KM, Porcelijn L, et al. C-reactive protein enhances IgG-mediated phagocyte responses and thrombocytopenia. Blood. 2015;125:1793–1802.
Wienzek-Lischka S, Konig IR, Papenkort EM, et al. HLA-DRB3*01:01 is a predictor of immunization against human platelet antigen-1a but not of the severity of fetal and neonatal alloimmune thrombocytopenia. Transfusion. 2017;57:533–540
Vinograd CA, Bussel JB. Antenatal treatment of fetal alloimmune thrombocytopenia: a current perspective. Haematologica. 2010;95:1807–1811.
Roberts I, Stanworth S, Murray NA. Thrombocytopenia in the neonate. Blood Rev. 2008;22:173–186
Scheffer, PG, Ait Soussan, A, Verhagen, OJ, et al. Noninvasive fetal genotyping of human platelet antigen‐1a. BJOG 2011; 118: 1392‐ 5.
Madsen, C, Prahm, KP, Nilsson, C, et al. [Establishing a screening programme in Denmark for foetal and neonatal alloimmune thrombocytopenia]. Ugeskr Laeger 2018; 180.
Kjeldsen‐Kragh, J. Screening for fetal and neonatal alloimmune thrombocytopenia: is it possible and what are the potential outcomes? ISBT Sci Ser 2018; 13: 187‐ 93.
Petermann R, Bakchoul T, Curtis BR, Mullier F, Miyata S, Arnold DM, Subcommittee on Platelet Immunology.Investigations for fetal and neonatal alloimmune thrombocytopenia : communication from the SSC of the ISTH, J Thromb Haemost. 2018; 16(12): 2526-2529
